Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Editorial

Mesenchymal stem cells in autoimmune diseases: hype or hope?

Hans U Scherer12, Melissa van Pel3 and René EM Toes1*

Author Affiliations

1 Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands

2 Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Charitéplatz 1, 10117 Berlin, Germany

3 Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands

For all author emails, please log on.

Arthritis Research & Therapy 2010, 12:126  doi:10.1186/ar3036


See related research by Schurgers et al., http://arthritis-research.com/content/12/1/R31

Published: 18 June 2010

Abstract

Intervention with mesenchymal stem cells (MSCs) represents a promising therapeutic tool in treatment-refractory autoimmune diseases. A new report by Schurgers and colleagues in a previous issue of Arthritis Research & Therapy sheds novel mechanistic insight into the pathways employed by MSCs to suppress T-cell proliferation in vitro, but, at the same time, indicates that MSCs do not influence T-cell reactivity and the disease course in an in vivo arthritis model. Such discrepancies between the in vitro and in vivo effects of potent cellular immune modulators should spark further research and should be interpreted as a sign of caution for the in vitro design of MSC-derived interventions in the setting of human autoimmune diseases.